Clinical re-assessment of combination scopolamine and chlorpromazine on heroin relapse

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000490

Enrollment

Unknown

Registered

2009-08-10

Start date

2009-07-21

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heroin addiction

Interventions

Group A:Combination scopolamine and chlorpromazine

Group B:Methadone replacement therapy

Eligibility

Sex/Gender

Male

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 55 years old, male or female; 2. Diagnosis is based on the DSM-IV - opioid dependence diagnostic criteria; 3. After 10-day acute detoxification; 4. Nomal physical and lab examination; 5. Negative urinary test for morphine; 6. Able and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy to medicine (including scopolamine,chlorpromazine and methadone); 2. Serious nervous diseases and mental disorders; 3. Poly-drug abuse ( more than 1 time per month); 4. Currently participating in other clinical trials; 5. Poor compliance, can not be in line with the interview.

Design outcomes

Primary

Measure	Time frame
Psychometrical scale for protracted withdrawal symptoms of opiate dependence;	—

Secondary

Measure	Time frame
Health survey, SAS and BDI scale, cognitive psychometrical form;	—

Countries

China

Contacts

Public ContactSheng Liu

lskingcn@yahoo.com.cn+86 0574 87145142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026